iBio报告2025年的成果强劲, 推动肥胖症治疗, iBio reports robust 2025 results, advances obesity treatments, and raises $100M on Nasdaq.

AI驱动的一家生物技术公司iBio报告了2025财政年度的强劲成果,并推进了肥胖症和心血管疾病管道。 iBio, an AI-driven biotech company, reported strong fiscal year 2025 results and advanced its obesity and cardiometabolic disease pipeline. 他们启动了双性抗体减重和肌肉保持方案,并披露了与AstralBio合作的一项有前途的阿米林受体抗体方案。 They launched a bispecific antibody program for weight loss and muscle preservation and disclosed a promising amylin receptor antibody program with AstralBio. 该公司迁至Nasdaq,筹集了多达1亿美元,扩大了领导团队。 The company moved to the Nasdaq, raising up to $100 million and expanding its leadership team. 有关其抗体IBIO-610的临床初步研究表明,脂肪选择性重量的大幅度减重,而没有造成重量损失。 Preclinical studies of their antibody IBIO-610 showed significant fat-selective weight loss without lean mass loss. 预计人类临床试验将在2026年底或2027年初开始。 Human clinical trials are anticipated to start in late 2026 or early 2027.